Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Atrial Fibrillation Market Research Report 2016

Tuesday, November 15, 2016 22:00
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Global Atrial Fibrillation Market

The Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. According to DelveInsight, Global Atrial Fibrillation market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. 

Try Sample Report @ https://www.wiseguyreports.com/sample-request/476536-atrial-fibrillation-market-insights-drugs-sales-forecast-af-2020

Coagulation is an important phenomenon of body to stop external bleeding but when clots are formed in blood vessels, it can be lethal. Blood clots in arteries can lead to heart attack and when formed in the blood vessels of brain can lead to stroke. Thus, anticoagulants are used to prevent the formation of blood clots in the body. Anticoagulants are proved to be a beneficial medication for the treatment of Atrial fibrillation, Deep Vein Thrombosis, Pulmonary Embolism and Stroke.

Key Coverage and Benefits:

  • The report will help in developing business strategies by understanding the trends shaping and driving the global Atrial Fibrillation (AF) market. 
    • Identifying patient populations in the global Atrial Fibrillation (AF) market to improve product design, pricing, and launch plans. 
    • Organize sales and marketing efforts by identifying the best opportunities for Atrial Fibrillation (AF) therapeutics in each of the markets covered. 
    • To understand the future market competition in the global Atrial Fibrillation (AF) therapeutics market and Insightful review of the key market drivers and barriers. 

Access Complete Report @ https://www.wiseguyreports.com/reports/476536-atrial-fibrillation-market-insights-drugs-sales-forecast-af-2020

Scope of the Report: 

• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management and current treatment options. 
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018. 
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2020. 
• It also provides Atrial fibrillation (AF) for United States, EU5 and Japan from 2015 and forecasted Market to 2020.

Executive Summary 
Market Share of Anticoagulants in 2015 and 2020 
Worldwide Market Share of Anticoagulants in 2015 
Worldwide Market Share of Anticoagulants in 2020 
Chapter 1 Anticoagulants Introduction 
Warfarin 
Low Molecular Weight Heparins 
New Oral Anticoagulants (NOAC) 
Chapter 2 Atrial Fibrillation 
Disease Overview 
Epidemiology of Atrial Fibrillation 
Treatment Landscape 
Treatment Algorithm 
Treatment Goals 
Treatment Details 
Chapter 3 Key Marketed Anticoagulants 
Novel Oral Anticoagulants Comparison 
Reversal Agents (Antidotes) 
Chapter 4 Anticoagulants Market Assessment by AF 
Key Findings 
Global Anticoagulants Market Sales by Atrial Fibrillation (AF) 
Global Anticoagulants Market Share (%) in Atrial Fibrillation 
Chapter 5 United States Anticoagulants Market Assessment by AF 
Key Findings 
United States Anticoagulants Market Sales by Atrial Fibrillation 
United States Anticoagulants Market Share (%) in Atrial Fibrillation 
Chapter 6 Europe 5 Anticoagulants Market Assessment by AF 
Key Findings 
Europe 5 Anticoagulants Market Sales by Atrial Fibrillation 
Europe 5 Anticoagulants Market Share (%) in Atrial Fibrillation 
Chapter 7 Japan Anticoagulants Market Assessment by AF 
Key Findings 
Japan Anticoagulants Market Sales by Atrial Fibrillation 
Japan Anticoagulants Market Share (%) in Atrial Fibrillation 
Chapter 8 Xarelto (rivaroxaban) Drug Profile 
Product Profile 
Advantages & Disadvantages 
Efficacy of Xarelto 
Safety of Xarelto 
Side effects of Drugs 
Cost of Therapy 
Global Drug Sales 
Xarelto Historical Sales and Forecasted Sales (2011-2020) 
Global Drug Sales by indication 
Xarelto Historical Sales and Forecasted Sales (2011-2020) by AF 
Clinical Trials Information 
SWOT Analysis of Xarelto 
Chapter 9 Pradaxa (dabigatran etexilate mesylate) Drug Profile 
Product Profile 
Advantages & Disadvantages 
Efficacy of Pradaxa 
Safety of Pradaxa 
Side effects of Drugs 
Cost of Therapy 
Global Drug Sales 
Pradaxa Historical Sales and Forecasted Sales (2011-2020) 
Global Drug Sales by indication 
Pradaxa Historical Sales and Forecasted Sales (2011-2020) by AF 
Clinical Trial Information 
SWOT Analysis of Pradaxa 
Chapter 10 Eliquis(Apixaban) Drug Profile 
Product Profile 
Advantages & Disadvantages 
Efficacy and Safety of Eliquis 
Side effects of Eliquis 
Cost of Therapy 
Global Drug Sales 
Eliquis Historical Sales and Forecasted Sales (2011-2020) 
Global Drug Sales by indication 
Eliquis Historical Sales and Forecasted Sales (2011-2020) by AF 
Clinical Trial Information 
SWOT Analysis of Eliquis 
Chapter 11 Savaysa (edoxaban tosylate) Drug Profile 
Product Profile 
Advantages & Disadvantages 
Efficacy of Savaysa 
Safety of Savaysa 
Side Effects of Savaysa 
Cost of Therapy 
Global Drug Sales 
Savaysa Historical Sales and Forecasted Sales (2011-2020) 
Global Drug Sales by indication 
Savaysa Historical Sales and Forecasted Sales (2011-2020) by AF 
Clinical Trial Information 
SWOT Analysis of Savaysa 
Chapter 12 Market Drivers and Constraints 
Factors Driving the Market Growth 
Factors Constraining the Market Growth 
Consulting Services 
Disclaimer 
About DelveInsight

Tables

Table 1 Key Marketed Anticoagulants 
Table 2 Comparison of NOACs & Warfarin 
Table 3 Global Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM) 
Table 4 Global Anticoagulants Sales in Atrial Fibrillation – 2015-2020 (USD MM) 
Table 5 US Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM) 
Table 6 US Anticoagulants Sales in Atrial Fibrillation – 2015-2020 (USD MM) 
Table 7 EU5 Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM) 
Table 8 EU5 Anticoagulants Sales in Atrial Fibrillation – 2015-2020 (USD MM) 
Table 9 Japan Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM) 
Table 10 Japan Anticoagulants Sales in Atrial Fibrillation – 2015-2020 (USD MM) 
Table 11 Xarelto Historical Sales and Forecasted Sales (2011-2020)(USD MM) 
Table 12 Xarelto Sales by Atrial Fibrillation (AF) (USD MM) 
Table 13 Xarelto, Clinical Trials by Zone, 2016 
Table 14 Pradaxa Historical Sales and Forecasted Sales (2011-2020)(USD MM) 
Table 15Pradaxa Sales by Atrial Fibrillation (AF) (USD MM) 
Table 16 Pradaxa, Clinical Trials by Zone, 2016 
Table 17 Eliquis Historical Sales and Forecasted Sales (2011-2020)(USD MM) 
Table 18Eliquis Sales by Atrial Fibrillation (AF) (USD MM) 
Table 19 Eliquis, Clinical Trials by Zone, 2016 
Table 20Savaysa Historical Sales and Forecasted Sales (2011-2020)(USD MM) 
Table 21SavaysaSales by Atrial Fibrillation (AF) (USD MM) 
Table 22 Savaysa, Clinical Trials by Zone, 2016

Figures 
Figure 1 Global Anticoagulants Sales in Atrial Fibrillation- 2011-2020 
Figure 2 Global Anticoagulants Market Share (%) in Atrial Fibrillation – 2011-2020 
Figure 3 US Anticoagulants Sales in Atrial Fibrillation- 2011-2020 
Figure 4 US Anticoagulants Market Share (%) in Atrial Fibrillation – 2011-2020 
Figure 5 EU5 Anticoagulants Sales in Atrial Fibrillation- 2011-2020 
Figure 6 EU5 Anticoagulants Market Share (%) in Atrial Fibrillation – 2011-2020 
Figure 7 Japan Anticoagulants Sales in Atrial Fibrillation- 2011-2020 
Figure 8 Japan Anticoagulants Market Share (%) in Atrial Fibrillation – 2011-2020 
Figure 9 Xarelto Historical Sales and Forecasted Sales (2011-2020) (USD MM) 
Figure 10 Xarelto Sales by Atrial Fibrillation (AF)(USD MM) 
Figure 11 Xarelto, Clinical Trials by Zone (%), 2016 
Figure 12 Pradaxa Historical Sales and Forecasted Sales (2011-2020) (USD MM) 
Figure 13 PradaxaSales by Atrial Fibrillation (AF)(USD MM) 
Figure 14 Pradaxa, Clinical Trials by Zone (%), 2016 
Figure 15 Eliquis Historical Sales and Forecasted Sales (2011-2020) (USD MM) 
Figure 16 EliquisSales by Atrial Fibrillation (AF)(USD MM) 
Figure 17 Eliquis, Clinical Trials by Zone (%), 2016 
Figure 18 SavaysaHistorical Sales and Forecasted Sales (2011-2020) (USD MM) 
Figure 19 SavaysaSales by Atrial Fibrillation (AF)(USD MM) 
Figure 20 Savaysa, Clinical Trials by Zone (%), 2016

Purchase Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=476536

For more information or any query mail at sales@wiseguyreports.com

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: 
https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.